Opinion|Videos|December 16, 2024

Preventing CRS and ICANS Across Sites of Care

Panelists discuss understanding institutional protocols for managing cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) prophylaxis in bispecific antibody therapy, along with criteria for safely selecting patients for outpatient step-up dosing.

Video content above is prompted by the following

  • What supportive care measures are utilized prophylactically at your institution for patients receiving bispecific antibodies to prevent CRS and ICANS?
  • What criteria would be important to consider when determining patient eligibility for outpatient administration of step-up dosing for bispecific antibodies, considering the higher risk of toxicities during this phase?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Latest CME